Drug Profile
MASL
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Sentrimed
- Class Antineoplastics; Lectins
- Mechanism of Action Membrane glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 13 Jul 2016 MASL is available for licensing as of 13 Jul 2016. http://www.sentrimed.com/
- 13 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)